Universal Beteiligungs und Servicegesellschaft mbH Has $8.11 Million Stock Holdings in PTC Therapeutics, Inc. $PTCT

Universal Beteiligungs und Servicegesellschaft mbH increased its position in PTC Therapeutics, Inc. (NASDAQ:PTCT) by 6.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 132,101 shares of the biopharmaceutical company’s stock after purchasing an additional 7,761 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.17% of PTC Therapeutics worth $8,107,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. boosted its stake in shares of PTC Therapeutics by 42.1% in the 2nd quarter. PNC Financial Services Group Inc. now owns 995 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 295 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in PTC Therapeutics by 247.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,143 shares of the biopharmaceutical company’s stock valued at $56,000 after buying an additional 814 shares during the period. Exchange Traded Concepts LLC acquired a new position in PTC Therapeutics in the third quarter valued at approximately $92,000. Globeflex Capital L P bought a new position in PTC Therapeutics in the second quarter valued at approximately $91,000. Finally, Plato Investment Management Ltd acquired a new stake in PTC Therapeutics during the 2nd quarter worth $92,000.

Insider Activity at PTC Therapeutics

In other PTC Therapeutics news, Director Glenn Md Phd Steele, Jr. sold 12,000 shares of the business’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $76.35, for a total transaction of $916,200.00. Following the transaction, the director owned 18,500 shares of the company’s stock, valued at $1,412,475. The trade was a 39.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Emma Reeve sold 15,666 shares of the company’s stock in a transaction that occurred on Thursday, October 30th. The shares were sold at an average price of $69.50, for a total value of $1,088,787.00. Following the completion of the sale, the director owned 6,666 shares in the company, valued at $463,287. This represents a 70.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 306,682 shares of company stock worth $24,139,117 over the last ninety days. Company insiders own 5.50% of the company’s stock.

PTC Therapeutics Stock Performance

Shares of NASDAQ PTCT opened at $75.25 on Monday. The stock has a 50 day moving average price of $77.17 and a 200 day moving average price of $64.76. The stock has a market capitalization of $6.04 billion, a PE ratio of 8.79 and a beta of 0.49. PTC Therapeutics, Inc. has a 52 week low of $35.95 and a 52 week high of $87.50.

PTC Therapeutics (NASDAQ:PTCT) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, beating the consensus estimate of ($1.19) by $1.39. The business had revenue of $211.01 million during the quarter, compared to analysts’ expectations of $177.42 million. PTC Therapeutics had a net margin of 42.25% and a negative return on equity of 194.11%. The firm’s revenue was up 7.2% on a year-over-year basis. During the same period last year, the business earned ($1.39) earnings per share. As a group, research analysts forecast that PTC Therapeutics, Inc. will post -4.52 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on PTCT shares. Weiss Ratings reissued a “hold (c)” rating on shares of PTC Therapeutics in a research note on Monday, December 29th. TD Cowen reaffirmed a “hold” rating on shares of PTC Therapeutics in a research note on Wednesday, November 5th. Royal Bank Of Canada lowered shares of PTC Therapeutics from an “outperform” rating to a “sector perform” rating and lifted their price objective for the stock from $82.00 to $91.00 in a research note on Monday, December 1st. Citigroup upped their target price on shares of PTC Therapeutics from $50.00 to $75.00 and gave the company a “neutral” rating in a research note on Wednesday, November 5th. Finally, Jefferies Financial Group increased their target price on shares of PTC Therapeutics from $63.00 to $77.00 and gave the stock a “buy” rating in a report on Tuesday, October 28th. Nine investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, PTC Therapeutics has an average rating of “Moderate Buy” and an average price target of $77.27.

PTC Therapeutics Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.